Early Career Travel Stipend Award
The Early Career Travel Stipend Awards have been established to provide funding for deserving young investigators to attend the ASPHO Conference, present their work, and introduce them to the many benefits of ASPHO programming and networking. Up to five awards of $500 will be given per year.
The qualifications for the award candidates are as follows:
- Applicant is either currently a fellow in a pediatric hematology/oncology program or is within 4 years of completing a standard three-year pediatric hematology/oncology fellowship
- Applicant's abstract has been accepted for presentation either as a poster or paper at the ASPHO meeting
- Applicant submits an application for the award
- Applicant is currently a member of ASPHO (at the time of submission) living in the United States or Canada
- Applicant has not received any other ASPHO awards this year
- Past recipients of this award are not eligible
To apply, complete the application, including:
- A supporting letter from the training program director or the program chair, attesting to the applicant’s status as well as their role in the conduct of the abstract research project
- The letter should address the individual’s interest in the abstract topic area and how participation at the ASPHO Conference will advance this area of their career
Winners are chosen by evaluation of the abstract submitted for presentation at the ASPHO Conference, together with review of each candidate’s research contributions and application materials. The award consists of $500 and a certificate of recognition.
Notes:
- Abstract must be submitted no later than January 12, 2023 at 3pm CT
- All award application materials must be received no later than January 12, 2023 at 3 pm CT
- Selected by the Conference Planning Committee
To be considered for the award:
- Carefully review the criteria for the award to determine eligibility
- Complete the Award Application Form
- Include all required supplemental materials to make your award application complete
2022 Recipients
Eman Al-Antary, MD
Children's Hospital of Michigan
Detroit, MI
NOVEL THERAPY FOR CYTARABINE-RESISTANT AML UTILIZING THE COMBINATION OF AZD5991 AND ONC213
Sharmila Raghunandan, DO MPH
Children's Healthcare of Atlanta/Emory University
Atlanta, GA
ABATACEPT FOR THE PREVENTION OF GVHD IN PEDIATRIC PATIENTS RECEIVING 7/8 HLA-MISMATCHED TRANSPLANT
Connor Hall, MD PhD
Johns Hopkins University School of Medicine
Baltimore, MD
MTHFR POLYMORPHISMS ARE ASSOCIATED WITH DECREASED METHOTREXATE TOLERANCE IN PEDIATRIC ALL
Roma Rajput, MD
Children's National Hospital
Washington, DC
STANDARDIZED THROMBOPROPHYLAXIS PROTOCOL IN MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN
Sherri Smart, MD PhD
Children's Healthcare of Atlanta/Emory University
Atlanta, GA
MERTK INHIBITIOR, MRX-2843, IS A POTENTIAL NOVEL THERAPY IN PEDIATRIC BONE SARCOMAS
Past Recipients
2021 Holly Edington, MD
Nura El-Haj, MD
Diana Fridlyand, MD
Sumit Gupta, MD
Peter Schoettler, MD
2020 Harry Lesmana, MD FAAP FACMG
Lisa Maurer, MD PhD
Mallery Olsen, MD
Anthony Sabulski, MD
Ryan Summers, MD
2019 Nathan A. Dahl, MD
Claudia Zapata, MD
Jeremy Rubinstein, MD PhD
Matthew Dietz, DO, MSEd
Regina M. Myers, MD
2018 Amy Houghtelin, MD
Zachary LeBlanc, MD
Joseph H. Oved, MD MA
Allison Remiker, MD
Luke R. Smart, MD
2017 Jason Schwartz, MD PhD
Ryan J. Summers, MD
Michael Deel, MD
2016 Waitman Aumann, MD
Jonathan Marron, MD
Pillai Pallavi Madhusoodhan, MD
Nickhill Bhakta, MD